HMGB1 and acute liver failure: In drug-induced acute liver failure and ACLF models, there were significant decreases in serum HMGB1 levels and a reduction in liver injury after intervention with the anti-HMGB1 antibody, which ultimately contributed to the significantly improved animal survival (Takano et al., 2010; Li et al., 2013).